Why the study?
Does dopexamine reduce the incidence of acute inflammation in the gut mucosa in high-risk patients undergoing abdominal surgery?
Does dopexamine reduce the incidence of acute inflammation in the gut mucosa in high-risk patients undergoing abdominal surgery?
Dopexamine infusion provides significant histologic protection to the upper gastrointestinal tract mucosa in high-risk patients undergoing abdominal surgery.
Dopexamine may protect upper GI mucosa in high-risk abdominal surgery; extends splanchnic perfusion data but needs clinical outcome trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Byers et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: